[Expression and Function of miR-181b in Diffuse Large B Cell Lymphoma].

Objective: To investigate the expression and function of miR-181b in diffuse large B cell lymphoma (DLBCL).

Methods: The lymphoid tissues of 124 patients with DLBCL examined and treated in our hospital from March 2010 to March 2012 were used as the DLBCL group. The healthy lympaid dissases in another 64 patients with non lymphaoma were selected as the control group. The expression levels of miR-181b in two groups were detected, and the expression levels of miR-181b in lymphoid tissues of DLBCL patients with different clinical features were compared. The survival of DLBCL patients with different levels of miR-181b expression was compared.

Results: The relative expression level of miR-181b in lymph tissues of DLBCL patients was significantly higher than that in healthy lymphoid tissues (P<0.05). The higher the Ann Arbor staging was, the higher the relative expression of miR-181b was in lymphoid tissues (P<0.05), and the higher the IPI score was, the higher the relative expression of miR-181b was in lymphoid tissues (P<0.05). The 5-year survival rate of the patients with miR-181b low expression was significantly higher than that of patients with miR-181b high expression (P<0.05).

Conclusion: There are differences in the expression of miR-181b in lymphoid tissues of DLBCL patients with different clinical stages and prognosis. It may become an effective indicator for the diagnosis and prognosis evaluation of DLBCL.